Cargando…
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
BACKGROUND: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual patient data (IPD) meta-analysis examines MR...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599727/ https://www.ncbi.nlm.nih.gov/pubmed/26449630 http://dx.doi.org/10.1186/s12885-015-1664-4 |
_version_ | 1782394306104918016 |
---|---|
author | Marinovich, Michael L. Macaskill, Petra Irwig, Les Sardanelli, Francesco Mamounas, Eleftherios von Minckwitz, Gunter Guarneri, Valentina Partridge, Savannah C. Wright, Frances C. Choi, Jae Hyuck Bhattacharyya, Madhumita Martincich, Laura Yeh, Eren Londero, Viviana Houssami, Nehmat |
author_facet | Marinovich, Michael L. Macaskill, Petra Irwig, Les Sardanelli, Francesco Mamounas, Eleftherios von Minckwitz, Gunter Guarneri, Valentina Partridge, Savannah C. Wright, Frances C. Choi, Jae Hyuck Bhattacharyya, Madhumita Martincich, Laura Yeh, Eren Londero, Viviana Houssami, Nehmat |
author_sort | Marinovich, Michael L. |
collection | PubMed |
description | BACKGROUND: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual patient data (IPD) meta-analysis examines MRI’s agreement with pathology in measuring the longest tumor diameter and compares MRI with alternative tests. METHODS: A systematic review of MEDLINE, EMBASE, PREMEDLINE, Database of Abstracts of Reviews of Effects, Heath Technology Assessment, and Cochrane databases identified eligible studies. Primary study authors supplied IPD in a template format constructed a priori. Mean differences (MDs) between tests and pathology (i.e. systematic bias) were calculated and pooled by the inverse variance method; limits of agreement (LOA) were estimated. Test measurements of 0.0 cm in the presence of pathologic residual tumor, and measurements >0.0 cm despite pathologic complete response (pCR) were described for MRI and alternative tests. RESULTS: Eight studies contributed IPD (N = 300). The pooled MD for MRI was 0.0 cm (LOA: +/−3.8 cm). Ultrasound underestimated pathologic size (MD: −0.3 cm) relative to MRI (MD: 0.1 cm), with comparable LOA. MDs were similar for MRI (0.1 cm) and mammography (0.0 cm), with wider LOA for mammography. Clinical examination underestimated size (MD: −0.8 cm) relative to MRI (MD: 0.0 cm), with wider LOA. Tumors “missed” by MRI typically measured 2.0 cm or less at pathology; tumors >2.0 cm were more commonly “missed” by clinical examination (9.3 %). MRI measurements >5.0 cm occurred in 5.3 % of patients with pCR, but were more frequent for mammography (46.2 %). CONCLUSIONS: There was no systematic bias in MRI tumor measurement, but LOA are large enough to be clinically important. MRI’s performance was generally superior to ultrasound, mammography, and clinical examination, and it may be considered the most appropriate test in this setting. Test combinations should be explored in future studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1664-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4599727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45997272015-10-10 Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis Marinovich, Michael L. Macaskill, Petra Irwig, Les Sardanelli, Francesco Mamounas, Eleftherios von Minckwitz, Gunter Guarneri, Valentina Partridge, Savannah C. Wright, Frances C. Choi, Jae Hyuck Bhattacharyya, Madhumita Martincich, Laura Yeh, Eren Londero, Viviana Houssami, Nehmat BMC Cancer Research Article BACKGROUND: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual patient data (IPD) meta-analysis examines MRI’s agreement with pathology in measuring the longest tumor diameter and compares MRI with alternative tests. METHODS: A systematic review of MEDLINE, EMBASE, PREMEDLINE, Database of Abstracts of Reviews of Effects, Heath Technology Assessment, and Cochrane databases identified eligible studies. Primary study authors supplied IPD in a template format constructed a priori. Mean differences (MDs) between tests and pathology (i.e. systematic bias) were calculated and pooled by the inverse variance method; limits of agreement (LOA) were estimated. Test measurements of 0.0 cm in the presence of pathologic residual tumor, and measurements >0.0 cm despite pathologic complete response (pCR) were described for MRI and alternative tests. RESULTS: Eight studies contributed IPD (N = 300). The pooled MD for MRI was 0.0 cm (LOA: +/−3.8 cm). Ultrasound underestimated pathologic size (MD: −0.3 cm) relative to MRI (MD: 0.1 cm), with comparable LOA. MDs were similar for MRI (0.1 cm) and mammography (0.0 cm), with wider LOA for mammography. Clinical examination underestimated size (MD: −0.8 cm) relative to MRI (MD: 0.0 cm), with wider LOA. Tumors “missed” by MRI typically measured 2.0 cm or less at pathology; tumors >2.0 cm were more commonly “missed” by clinical examination (9.3 %). MRI measurements >5.0 cm occurred in 5.3 % of patients with pCR, but were more frequent for mammography (46.2 %). CONCLUSIONS: There was no systematic bias in MRI tumor measurement, but LOA are large enough to be clinically important. MRI’s performance was generally superior to ultrasound, mammography, and clinical examination, and it may be considered the most appropriate test in this setting. Test combinations should be explored in future studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1664-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-08 /pmc/articles/PMC4599727/ /pubmed/26449630 http://dx.doi.org/10.1186/s12885-015-1664-4 Text en © Marinovich et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Marinovich, Michael L. Macaskill, Petra Irwig, Les Sardanelli, Francesco Mamounas, Eleftherios von Minckwitz, Gunter Guarneri, Valentina Partridge, Savannah C. Wright, Frances C. Choi, Jae Hyuck Bhattacharyya, Madhumita Martincich, Laura Yeh, Eren Londero, Viviana Houssami, Nehmat Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
title | Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
title_full | Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
title_fullStr | Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
title_full_unstemmed | Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
title_short | Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
title_sort | agreement between mri and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599727/ https://www.ncbi.nlm.nih.gov/pubmed/26449630 http://dx.doi.org/10.1186/s12885-015-1664-4 |
work_keys_str_mv | AT marinovichmichaell agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT macaskillpetra agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT irwigles agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT sardanellifrancesco agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT mamounaseleftherios agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT vonminckwitzgunter agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT guarnerivalentina agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT partridgesavannahc agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT wrightfrancesc agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT choijaehyuck agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT bhattacharyyamadhumita agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT martincichlaura agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT yeheren agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT londeroviviana agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis AT houssaminehmat agreementbetweenmriandpathologicbreasttumorsizeafterneoadjuvantchemotherapyandcomparisonwithalternativetestsindividualpatientdatametaanalysis |